Aripiprazole (Abilify) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder

Trial Profile

Aripiprazole (Abilify) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Dec 2015 Planned End Date changed from 1 Feb 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.
    • 07 Dec 2015 Planned primary completion date changed to 1 Mar 2016 as per ClinicalTrials.gov record.
    • 12 Apr 2013 Planned End Date changed from 1 Feb 2013 to 1 Feb 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top